Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2015 Feb;32(1):5-7.
doi: 10.1177/1049909113504240. Epub 2013 Sep 19.

Dronabinol Treatment of Refractory Nausea and Vomiting Related to Peritoneal Carcinomatosis

Affiliations
Case Reports

Dronabinol Treatment of Refractory Nausea and Vomiting Related to Peritoneal Carcinomatosis

Sarah L Hernandez et al. Am J Hosp Palliat Care. .

Abstract

Nausea and vomiting are common and often highly distressing symptoms in advanced cancer and in hospice and palliative medicine practice. Nausea and vomiting generally respond well to correction of the underlying etiology (when possible) and appropriate selection of antiemetic medication, but up to 7% of patients will have refractory symptoms. Dronabinol is extensively studied for chemotherapy-related nausea and vomiting, but there are only a few case reports of its use in nausea and vomiting unrelated to chemotherapy. We report a patient with end-stage ovarian cancer with peritoneal carcinomatosis and refractory nausea and vomiting who responded dramatically to addition of dronabinol. Dronabinol is usually well tolerated and may have several novel mechanisms of antiemetic action; further study of its scope of efficacy is warranted.

Keywords: anandamide; dronabinol; endocannabinoids; nausea; ovarian cancer; peritoneal carcinomatosis; vomiting.

Similar articles

See all similar articles

Cited by 3 articles

Publication types

Feedback